Stallergenes Greer is governed by a Board of Directors which determines the strategic direction of the Group.
The Executive Committee, chaired by the Chief Executive Officer, is comprised of senior leaders who represent a breadth and depth of knowledge and experience to lead our business. Together, they form a forward-thinking, collaborative, multicultural group of leaders that drive our culture of success and support our growth worldwide.
Chief Executive Officer
Michele Antonelli has been CEO of Stallergenes Greer since January 2019. He joined the company in 2015 as Head of Europe and International. Previously, Michele Antonelli held roles of increasing responsibility and scope at UCB, most recently serving as EVP and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as SVP and Global Head of Biotech Manufacturing and Process Development.
Michele Antonelli is Swiss and Italian.
Executive Vice President Operations, Europe and International
Amer Jaber joined Stallergenes Greer in 2018. Prior to joining Stallergenes Greer, Amer Jaber was Head of Biotechnology Operations at R-Pharm responsible for developing the long-term strategy and execution of technical operations for CMC Development and Manufacturing. Amer Jaber was previously Head of Global Biotech Development and Manufacturing for Technical Operations and Managing Director of UCB Switzerland. Before joining UCB, he held roles of increasing responsibility at Mondobiotech, Serono International and Rivopharm.
Amer Jaber is Lebanese and Swiss.
General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access
Dominique Pezziardi joined Stallergenes Greer in 2012 as Head of Strategy and Business Operations. Prior to joining Stallergenes Greer, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, rare diseases, cardiology and medical devices in the pharmaceutical sector at Ciba, Sanofi and Merck Serono. He successfully managed global product launches, life cycle development plans, mature franchise relaunches, alliances with strategic partners, and more recently, corporate strategy development.
Dominique Pezziardi is French.
Executive Vice President, Head of Americas
Tibor Nemes joined Stallergenes Greer in 2016 and served as Global Head of Technical Operations before taking over as Head of the Americas in May 2018. Tibor Nemes previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A. Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at Novavax, Inc., Bristol- Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.
Tibor Nemes is American.
Valérie Benhamou joined Stallergenes Greer in 2017 as Associate General Counsel Europe and International. Valérie Benhamou joined the company from Abbott, where she was Senior Legal Counsel for France, Benelux and Africa. Prior to Abbott, she served as Senior counsel for Bristol-Myers Squibb where she provided legal support to all divisions in France and to EMEA commercial operations and practiced at law firms where she focused on healthcare matters. She has been a member of the Paris Bar since 1999.
Valérie Benhamou is French.
Chief Financial Officer
Nicola Lamacchia joined Stallergenes Greer in 2017 as Head of Finance for the Europe and International region. Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company’s growth and expansion. Prior to Shire, Nicola Lamacchia held several country, regional and divisionlevel financial roles at Merck Serono.
Nicola Lamacchia is Swiss and Italian.
Senior Vice President, Human Resources
Jérôme Tilly joined Stallergenes Greer in 2014 as Senior Vice President Human Resources, Europe and International. Jérôme Tilly joined the company from Sogefi, an Italian automotive supplier, where he served as Vice President Human Resources. Throughout his career, Jérôme Tilly held positions of increasing responsibility and gained in-depth knowledge of human resources at automotive, airport ground handling and media companies.
Jérôme Tilly is French.
Senior Vice President, Commercial Operations, Europe and International
Petr Tor joined Stallergenes Greer in 2010 as General Manager of the Czech and Slovak subsidiary and since 2014 he has held commercial responsibilities for various regions of increasing scope and complexity in Europe, the Middle East and Africa. Petr Tor gained his expertise in several therapeutic fields including asthma, cardiology, diabetes, glaucoma, antibiotics and HIV at Merck & Co., where he spent 16 years.
Petr Tor is Czech.
Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by the B-FLEXION group. B-FLEXION is a private, entrepreneurial investment firm, delivering exceptional value over the generations, while also contributing positively to society.
B-FLEXION continues to drive expansion by growing operating businesses in transformative industries. In keeping with – and building upon – its heritage, these are principally in the fields of life sciences, healthcare services and digital health.
Chaired by Ernesto Bertarelli, B-FLEXION has offices across Europe and in the United States.